Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Harrow, Inc. has issued $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 in a private offering. These New Notes were sold to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.
The New Notes are fungible with Harrow’s existing $250,000,000 aggregate principal amount of 8.625% Senior Notes due 2030 and were issued under the same indenture. Harrow received approximately $48.7 million in net proceeds and plans to use the funds for general corporate purposes, including growth initiatives, product development, strategic business opportunities and related investments.
Harrow Inc: Amendment No. 1 to a Schedule 13G/A was filed reporting that The Vanguard Group beneficially owns 0 shares of Harrow Inc common stock after an internal realignment effective January 12, 2026.
The filing explains that certain Vanguard subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Harrow, Inc. has priced a private offering of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030. The new notes will be issued as additional notes under the same indenture as the existing $250,000,000 8.625% notes, forming a single series with identical terms apart from issuance date and issue price.
The notes, guaranteed by certain current and future restricted subsidiaries, are expected to close on March 27, 2026, bear interest at 8.625% and mature on September 15, 2030, with semi-annual cash interest payments on March 15 and September 15. Harrow plans to use the net proceeds for general corporate purposes, including potential growth initiatives, product development and strategic business opportunities. The offering is being made only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
Harrow, Inc. is launching a private add-on debt offering, seeking to sell $50.0 million in aggregate principal amount of additional 8.625% senior unsecured notes due 2030. These new notes will form a single series with the existing $250,000,000 of 2030 notes issued in September 2025 under the same indenture.
The notes will be offered only to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S. Harrow plans to use net proceeds for general corporate purposes, including growth initiatives, product development, strategic business opportunities, and related investments, though completion of the offering remains subject to market and other conditions.
Harrow, Inc. Schedule 13G reports that Daniel Kaufman beneficially owns 1,878,000 shares of Common Stock, representing 5.04% as of 03/10/2026.
The filing lists Kaufman’s sole voting and dispositive power over the 1,878,000 shares. The address and CUSIP are provided in the disclosure.
Harrow, Inc. filed a current report to furnish an updated corporate investor presentation under Regulation FD. The presentation, dated March 2026, is provided as Exhibit 99.1 and may be used by management in investor conferences and meetings.
The company specifies that this material is being furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is only incorporated into other securities filings if expressly referenced.
Opaleye Management Inc., a 10% owner of HARROW, INC., reported open-market sales of Harrow common stock through affiliated entities on March 3 and 4, 2026.
Opaleye, L.P. sold 59,000 and 134,000 shares at weighted average prices of $39.1524 and $39.6721, while a separately managed account sold 1,309 and 4,263 shares at the same respective weighted average prices. In total, 198,572 shares were sold in multiple transactions within disclosed price ranges.
HARROW, INC. insider Opaleye Management Inc., as portfolio manager of a separately managed account, reported an open-market sale of 5,000 shares of common stock on February 27, 2026 at a price of $54.18 per share.
After this sale, the managed account held 65,000 shares indirectly attributed to Opaleye. A separate holding of 3,815,000 shares is owned directly by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Harrow, Inc. outlines its position as a North American leader in ophthalmic disease management, combining branded pharmaceuticals with its ImprimisRx compounding business. The company markets numerous FDA-approved eye products and is building a late-stage pipeline, highlighted by MELT-300 for non‑IV, non‑opioid sublingual procedural sedation.
MELT-300 has completed Phase 3 under a Special Protocol Assessment, with an NDA planned for the first half of 2027 and a targeted U.S. launch in the second half of 2028. Harrow also plans mid‑2026 and mid‑2027 launches for BYOOVIZ and OPUVIZ biosimilars and BYQLOVI for post‑operative inflammation.
In November 2025, Harrow acquired the remaining equity of Melt Pharmaceuticals for an initial $4.3 million cash payment plus potential milestone-based cash and equity tied to MELT‑300 approval, reimbursement, and sales. Research and development expenses rose to $20.94 million in 2025 from $12.23 million in 2024 and $6.652 million in 2023, reflecting increased investment in pipeline assets and the Melt acquisition.
The company reports two segments—Branded and ImprimisRx—both U.S.-based, and had 373 employees as of February 25, 2026. Harrow emphasizes regulatory and reimbursement complexity, competition from larger pharmaceutical and biosimilar players, and evolving federal and state pharmacy rules, especially around its 503A/503B compounding facilities, as key risks to growth and profitability.
Harrow, Inc. reported strong growth for Q4 and full-year 2025 and issued 2026 guidance. Quarterly revenue reached $89.1 million, up 33% from $66.8 million, while full-year revenue rose 36% to $272.3 million from $199.6 million. Q4 GAAP net income was $6.6 million, though the company posted a $5.1 million net loss for 2025. Adjusted EBITDA grew to $24.2 million in Q4 and $61.9 million for the year. Operating cash flow swung to a positive $43.9 million in 2025 from $(22.2) million in 2024, and cash and cash equivalents were $72.9 million at year-end. Management highlighted strong momentum in key ophthalmic brands VEVYE, IHEEZO and TRIESENCE and outlined plans to expand sales teams and invest in growth initiatives. For 2026, Harrow guides to $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA, with results expected to be more heavily weighted to the second half of the year.